LOGO
LOGO

Will CorMedix's Strategic Acquisition Fuel A New Era Of Growth?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
acquisition 21102025 lt

With a bold strategic acquisition, this commercial-stage company has taken a transformative leap - broadening its revenue base with synergistic assets and positioning itself for sustained, long-term growth.

The company we are profiling today is CorMedix Inc. (CRMD), whose lead product is DefenCath, indicated for the prevention of catheter-related bloodstream infections in patients undergoing hemodialysis through a central venous catheter.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.

RELATED NEWS